市場調查報告書
商品編碼
1178755
切片穿刺針的全球市場:市場規模(各產品,各用途,各最終用途),各地區的展望,產業分析,成長性,競爭市場佔有率,預測(2023年~2032年)Biopsy Needle Market Size By Product, By Application, By End-use, Regional Outlook, Industry Analysis Report, Growth Potential, Competitive Market Share & Forecast, 2023 - 2032 |
全球切片穿刺針市場,由於開發新切片穿刺針的技術不斷進步,2023年~2032年之間預計表現大幅成長。
還有組織掃描和小癌症腫瘤檢測的創新技術的利用可能性,在預測期間內支援產業的成長。此外,高所得國的政府和公共醫療保險公司所提供的幾個償付政策和獎勵,更加將推進切片穿刺針市場擴大。
本報告提供全球切片穿刺針市場相關調查分析,產業的考察,市場區隔分析,地區分析,企業簡介等資訊。
Biopsy Needle Market is slated to demonstrate massive growth between 2023 and 2032, owing to the constant technological advancements for developing novel biopsy needles. In addition, the availability of innovative technologies for tissue scanning and detecting small cancerous tumors will bolster the industry growth over the forecast period.
Besides, several reimbursement policies and incentives offered by governments or public health insurance firms in high-income countries are further slated to propel the biopsy needles market expansion.
The competitive landscape of the biopsy needle market is highly intact. Key players in the market are constantly engaging in strategic initiatives, including partnerships, mergers and acquisitions, and product launches, to strengthen their market positions. For instance, in December 2022, Olympus Corporation announced inking a definitive agreement to acquire Odin Vision, a cloud-based AI endoscopy company, in a deal worth USD 79 million in upfront and milestone-based payments.
In yet another example, Boston Scientific received FDA approval for the extended labeling of the WATCHMAN FLX™ LAAC Device, which can be used for dual anti-platelet therapy as a medication after the procedure.
Overall, the biopsy needle market is classified in terms of product, application, end-user, and region.
On the basis of product, the market share from biopsy needles segment is slated to grow exponentially over the foreseeable period. The multiple benefits offered by biopsy needles including high cost affordability and robust operational speed would boost the product demand in the ensuing years.
Considering the application, the cancer/tumor segment held approximately 50% of the market share in 2022 and is expected to grow considerably through 2032. Needle biopsy reveals whether a lump or mass is an infection, a cyst, a benign tumor, or cancer, which is expected to propel segment growth substantially. In addition, the introduction of several new cancer diagnosis centers and products by leading market players is estimated to propel the segmental growth in the future.
Based on the end-user, the hospital segment is expected to register massive growth through 2032. Needle biopsies are performed using CT scan, MRI, mammogram, or ultrasound, which can be done easily in hospitals, further supporting the segmental expansion in the coming years.
Regionally, the North America biopsy needle market held over 48% market share in 2022 and is slated to demonstrate massive growth through 2032. This can be attributed to the constant product development in the healthcare sector, rising awareness regarding infectious diseases, and increasing application of point-of-care diagnostic devices for safe and early disease detection. In addition, the presence of several established key players and highly developed co-payment and insurance systems will positively impact the overall market outlook in the region.